Title (en)

SUBSTITUTED TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D?3 RECEPTORS

Title (de)

SUBTITUIERTE TETRAHYDROISOCHINOLINEDERIVATE ALS DOPAMINE D3 REZEPTOR-MODULATOREN

Title (fr)

DERIVES DE TETRAHYDRO-ISOQUINOLINE SUBSTITUEE, UTILES EN TANT QUE MODULATEURS DES RECEPTEURS D 3? DE LA DOPAMINE

Publication

EP 0981516 A1 20000301 (EN)

Application

EP 98929278 A 19980427

Priority

- EP 9802581 W 19980427
- GB 9708694 A 19970430

Abstract (en)

[origin: WO9849145A1] Compounds of formula (I), wherein R<1> represents a substituent selected from a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C1-4alkyl, C1-4alkoxy, arylC1-4alkoxy, C1-4alkylthio, C1-4alkoxyC1-4alkyl, C3-6cycloalkylC1-4alkoxy, C1-4alkanoyl, C1-4alkoxycarbonyl, C1-4alkylsulphonyl, C1-4alkylsulphonyloxy, C1-4alkylsulphonylC1-4alkyl, arylsulphonyl, arylsulphonyloxy, arylsulphonylC1-4alkyl, C1-4alkylsulphonamido, C1-4alkylamido, C1-4alkylsulphonamidoC1-4alkyl, C1-4alkylamidoC1-4alkyl, arylsulphonamido, arylcarboxamido, arylsulphonamidoC1-4alkyl, arylcarboxamidoC1-4alkyl, aroyl, aroylC1-4alkyl, or arylC1-4alkanoyl group; a group R<3>OCO(CH2)p, R<3>CON(R<4>)(CH2)p, R<3>R<4>NCO(CH2)p or R<3>R<4>NSO2(CH2)p where each of R<3> and R<4> independently represents a hydrogen atom or a C1-4alkyl group or R<3>R<4> forms part of a C3-6 azacycloalkane or C3-6(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar<1>Z, wherein Ar<1> represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring and z represents a bond, O, S, or CH2; R<2> represents a hydrogen atom or a C1-4alkyl group; q is 1 or 2; Ar represents an optionally substituted phenyl ring or an optionally substituted 5- or 6-membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; and salts thereof. Compounds of formula (I) and their salts have affinity for dopamine receptors, in particular the D3 receptor, and thus potential in the treatment of conditions wherein modulation of the D3 receptor is beneficial, e.g. as antipsychotic agents.

IPC 1-7

C07D 217/04; C07D 401/12; C07D 409/12; A61K 31/47

IPC 8 full level

A61K 31/4725 (2006.01); **A61P 25/18** (2006.01); **A61P 43/00** (2006.01); **C07D 217/04** (2006.01); **C07D 401/12** (2006.01); **C07D 409/12** (2006.01)

CPC (source: EP)

A61P 25/18 (2017.12); **A61P 43/00** (2017.12); **C07D 217/04** (2013.01); **C07D 401/12** (2013.01); **C07D 409/12** (2013.01)

Citation (search report)

See references of WO 9849145A1

Cited by

US10870660B2; US11345716B2; US11897899B2

Designated contracting state (EPC)

BE CH DE ES FR GB IT LI NL

DOCDB simple family (publication)

WO 9849145 A1 19981105; CA 2288308 A1 19981105; EP 0981516 A1 20000301; GB 9708694 D0 19970618; JP 2001522366 A 20011113

DOCDB simple family (application)

EP 9802581 W 19980427; CA 2288308 A 19980427; EP 98929278 A 19980427; GB 9708694 A 19970430; JP 54662098 A 19980427